Articles for tag: Aims, Approval, Banks, CEO, Crucial, Era, Growth, heralds, IndusInd, Kathpalias, Pending, RBI, reappointment, Sumant, Transformative

Market News

Sumant Kathpalia’s reappointment as IndusInd Bank’s CEO heralds a crucial era, pending RBI approval, as he aims for transformative growth.

Sumant Kathpalia’s reappointment as IndusInd Bank’s CEO heralds a crucial era, pending RBI approval, as he aims for transformative growth.

IndusInd Bank has announced the re-appointment of Sumant Kathpalia as its managing director and chief executive officer for another three years, effective March 24, 2025, pending necessary approvals from the Reserve Bank of India and shareholders. Kathpalia has held the position since March 2020 and previously received a two-year extension in March 2023. Under his ...

Market News

ZEE and Sony’s .5 billion merger collapses as NCLT recalls approval, ending a turbulent legal saga.

ZEE and Sony’s $10.5 billion merger collapses as NCLT recalls approval, ending a turbulent legal saga.

The National Company Law Appellate Tribunal (NCLAT) has allowed Axis Finance, IDBI Bank, and IDBI Trusteeship Services to withdraw their petitions against the merger of Zee Entertainment and Sony Pictures Networks India. This decision follows the Mumbai Bench of the National Company Law Tribunal (NCLT), which had previously approved the merger on August 10, 2023, ...

Market News

IIFL Finance, a key non-bank lender, regains RBI approval for gold loans, overcoming scrutiny to restore vital business operations.

IIFL Finance, a key non-bank lender, regains RBI approval for gold loans, overcoming scrutiny to restore vital business operations.

IIFL Finance, a leading non-bank lender, recently announced that the Reserve Bank of India (RBI) has lifted restrictions on its gold loan operations. These limitations were imposed in March 2024 due to concerns about the accuracy of gold evaluations and compliance with regulations. With the RBI’s decision now effective, IIFL Finance can resume its activities ...

Market News

Aditya Birla Capital secures RBI approval for merging with its subsidiary, poised to enhance capital adequacy and streamline operations.

Aditya Birla Capital secures RBI approval for merging with its subsidiary, poised to enhance capital adequacy and streamline operations.

Aditya Birla Capital Ltd (ABCL) has received approval from the Reserve Bank of India (RBI) for merging its wholly owned subsidiary, Aditya Birla Finance Ltd (ABFL), into itself. This merger aims to create a larger and more efficient non-banking financial company. ABFL is classified as an upper layer NBFC and is required to be listed ...

Market News

The NCLT reverses approval of the Zee-Sony merger as parties agree to withdraw due to unresolved disputes. Dramatic fallout ensues.

The NCLT reverses approval of the Zee-Sony merger as parties agree to withdraw due to unresolved disputes. Dramatic fallout ensues.

The National Company Law Tribunal (NCLT) recently approved the withdrawal of its order regarding the merger between Zee Entertainment and Sony Pictures Networks India. This decision follows an agreement between the two companies to resolve their six-month dispute over a failed USD 10 billion merger. The NCLT recalled its earlier approval from August 10, 2023, ...

Market News

Strides Pharma secures overwhelming approval to launch OneSource, a pivotal CDMO, as it seeks final nod from NCLT for growth.

Strides Pharma secures overwhelming approval to launch OneSource, a pivotal CDMO, as it seeks final nod from NCLT for growth.

Strides Pharma Science announced that it has received overwhelming approval from shareholders and secured creditors for the formation of OneSource, a specialty contract development and manufacturing organization (CDMO). This decision comes after meetings facilitated by the National Company Law Tribunal (NCLT). The creation of OneSource will integrate the Oral Technologies business from Strides, Sterile Injectables ...

Market News

Zydus Gains FDA Approval for Scopolamine Patch, Tapping .6M Market

Zydus Gains FDA Approval for Scopolamine Patch, Tapping $69.6M Market

Zydus Lifesciences Ltd has secured final approval from the US FDA to Market its Scopolamine transdermal system, designed to prevent nausea and vomiting in various situations, including after surgery and due to motion sickness. The product, which delivers 1 mg over 3 days, will be manufactured at Zydus’ facility in Ahmedabad. This marks the fifth ...

DeFi Explained: Simple Guide Green Crypto and Sustainability China’s Stock Market Rally and Outlook The Future of NFTs The Rise of AI in Crypto